HERNÁNDEZ-SÁNCHEZ, M., Lenka RADOVÁ, Jana KOTAŠKOVÁ, D. TAMBORERO, A.E. RODRIGUEZ, Karla PLEVOVÁ, M. ABÁIGAR, Vasileios BIKOS, R. BENITO, Sylvia TAKÁČOVÁ, M. QUIJADA, A. ÁFRICA MARTÍN, M. ALCOCEBA, A. GARCÍA DE COCA, Michael DOUBEK, M. GONZÁLEZ, N. LOPEZ-BIGAS, Šárka POSPÍŠILOVÁ and J. HERNÁNDEZ-RIVAS. Analysis of clonal evolution in chronic lymphocytic leukemia from inactive to symptomatic disease prior treatment using whole-exome sequencing. In Blood (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016). 2016.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Analysis of clonal evolution in chronic lymphocytic leukemia from inactive to symptomatic disease prior treatment using whole-exome sequencing.
Authors HERNÁNDEZ-SÁNCHEZ, M., Lenka RADOVÁ, Jana KOTAŠKOVÁ, D. TAMBORERO, A.E. RODRIGUEZ, Karla PLEVOVÁ, M. ABÁIGAR, Vasileios BIKOS, R. BENITO, Sylvia TAKÁČOVÁ, M. QUIJADA, A. ÁFRICA MARTÍN, M. ALCOCEBA, A. GARCÍA DE COCA, Michael DOUBEK, M. GONZÁLEZ, N. LOPEZ-BIGAS, Šárka POSPÍŠILOVÁ and J. HERNÁNDEZ-RIVAS.
Edition Blood (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016), 2016.
Other information
Type of outcome Conference abstract
Confidentiality degree is not subject to a state or trade secret
Organization unit Central European Institute of Technology
Changed by Changed by: Jana Dvořáková, učo 112653. Changed: 19/4/2018 11:34.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
TE02000058, research and development projectName: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED)
Investor: Technology Agency of the Czech Republic
15-31834A, interní kód MU
(CEP code: NV15-31834A)
Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie
Investor: Ministry of Health of the CR
306242, interní kód MUName: NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: European Union, Cooperation
7E13008, research and development projectName: Next Generation Sequencing Platform for Targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 30/5/2024 05:07